España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
AbCellera Biologics
ABCL
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$3.23
0.03
0.94%
At close: -
$3.28
0.05
1.50%
After Hours: 5:16 PM EDT
Get Report
Comment
AbCellera Biologics (ABCL) Forecast
News
Earnings
AbCellera Biologics (ABCL) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for AbCellera Biologics (NASDAQ:ABCL) Stock
AbCellera Biologics Stock (NASDAQ: ABCL)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, January 15, 2025
AbCellera Biologics shares are trading higher...
Benzinga Newsdesk
Monday, January 13, 2025
AbCellera Expands AbbVie Collaboration To Inc...
Benzinga Newsdesk
Wednesday, January 08, 2025
Keybanc Maintains Overweight on AbCellera Bio...
Benzinga Newsdesk
Thursday, December 12, 2024
Watching AbCellera Biologics; Shares See Volu...
Benzinga Newsdesk
Thursday, November 07, 2024
AbCellera Unveils Data At SITC 2024 On T-Cell...
Benzinga Newsdesk
Tuesday, November 05, 2024
Benchmark Reiterates Hold on AbCellera Biolog...
Benzinga Newsdesk
Stifel Reiterates Buy on AbCellera Biologics,...
Benzinga Newsdesk
Monday, November 04, 2024
AbCellera Biologics Q3 2024 GAAP EPS $(0.17) ...
Benzinga Newsdesk
Tuesday, October 22, 2024
CORRECTION: Abacus Life Ticker Is 'ABL'
Benzinga Newsdesk
Friday, October 04, 2024
AbCellera Announces Presentation On T-cell En...
Benzinga Newsdesk
Tuesday, August 20, 2024
This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Avi Kapoor
Benchmark Downgrades AbCellera Biologics to H...
Benzinga Newsdesk
Tuesday, August 06, 2024
AbCellera Biologics Q2 EPS $(0.13) Beats $(0....
Benzinga Newsdesk
Wednesday, July 31, 2024
AbCellera And Lilly Expand Collaboration To D...
Benzinga Newsdesk
Thursday, July 11, 2024
Keybanc Maintains Overweight on AbCellera Bio...
Benzinga Newsdesk
Wednesday, May 08, 2024
Keybanc Maintains Overweight on AbCellera Bio...
Benzinga Newsdesk
Tuesday, May 07, 2024
AbCellera Biologics Q1 2024 GAAP EPS $(0.14) ...
Benzinga Newsdesk
Monday, April 08, 2024
AbCellera Presents Data On T-Cell Engagers Ag...
Benzinga Newsdesk
Monday, March 11, 2024
AbCellera To Collaborate With Biogen To Disco...
Benzinga Newsdesk
Thursday, February 22, 2024
Benchmark Upgrades AbCellera Biologics to Buy
Benzinga Newsdesk
Wednesday, February 21, 2024
AbCellera Biologics shares are trading lower ...
Benzinga Newsdesk
Tuesday, February 20, 2024
Recap: AbCellera Biologics Q4 Earnings
Benzinga Insights
AbCellera Biologics Q4 2023 GAAP EPS $(0.17) ...
Benzinga Newsdesk
Earnings Scheduled For February 20, 2024
Benzinga Insights
Tuesday, December 05, 2023
Keybanc Initiates Coverage On AbCellera Biolo...
Benzinga Newsdesk
Thursday, November 09, 2023
AbCellera Biologics Director Trades Company's Stock
Benzinga Insights
Friday, November 03, 2023
AbCellera Presents New Data On Two T-Cell Eng...
Benzinga Newsdesk
AbCellera shares are trading lower after the ...
Benzinga Newsdesk
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
Thursday, November 02, 2023
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
AbCellera shares are trading lower after the ...
Benzinga Newsdesk
AbCellera Biologics Q3 EPS $(0.10) Beats $(0....
Benzinga Newsdesk
Earnings Scheduled For November 2, 2023
Benzinga Insights
Wednesday, November 01, 2023
Prelude Therapeutics And AbCellera Enter Part...
Benzinga Newsdesk
Friday, October 13, 2023
Piper Sandler Assumes AbCellera Biologics at ...
Benzinga Newsdesk
Abcellera Biologics On Sept 18 Took Ownership Of Antibody Drug Candidate That Was Discovered By Co As Part Of Its Collaboration With EQRX; Advancing Antibody Drug Candidate Into Ind-enabling Studies
Charles Gross
Tuesday, October 03, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Monday, October 02, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
Thursday, September 28, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
Wednesday, September 27, 2023
Board Member of AbCellera Biologics Purchased $98K In Stock
Benzinga Insights
Tuesday, September 26, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Thursday, September 21, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
Wednesday, September 20, 2023
AbCellera Expands Multi-Target Antibody Disco...
Benzinga Newsdesk
Tuesday, September 19, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Friday, September 15, 2023
AbCellera Biologics Chief Operating Officer Trades Company's Stock
Benzinga Insights
Wednesday, September 13, 2023
AbCellera Announces Collaboration With Incyte...
Benzinga Newsdesk
Monday, September 11, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
Thursday, August 31, 2023
Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term Prospects
Nabaparna Bhattacharya
Benchmark Maintains Buy on AbCellera Biologic...
Benzinga Newsdesk
Tuesday, August 22, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Show More
